CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
ANNEX 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
The Member States should ensure that all conditions or restrictions with regard to the safe and 
effective use of the medicinal product described below are implemented: 
The Marketing Authorisation Holder (MAH) shall agree the details of a controlled distribution system 
for the 20 ml vial of Revatio 0.8 mg/ml solution for injection with the National Competent Authorities 
and  must  implement  such  programme  nationally  to  ensure  that  prior  to  prescribing  all  health  care 
professionals  who  intend  to  prescribe  and/or  dispense  Revatio  0.8 mg/ml  solution  for  injection  are 
provided the following: 
Information for Healthcare professionals 
- 
-  Copy of the Summary of Product Characteristics (SPC) 
-  Data  Capture  Form  (DCF)  designed  to  facilitate  reporting  of  events  of  hypotension  and 
associated problems 
The Information for Healthcare professionals should contain the following key elements: 
- 
- 
Information about the Pharmacovigilance Monitoring Programme regarding the potential risk 
of clinically relevant hypotension and related problems to be put into place with the use of the 
DCF.  
Information on the switch from the 50 ml vial to the 20 ml vial for Revatio 0.8 mg/ml solution 
The Marketing Authorisation Holder shall agree the information for healthcare professionals, and the 
healthcare professionals to be targeted,  with the national competent authority of each Member State 
prior to the launch of the 20 ml vial of Revatio 0.8 mg/ml solution for injection in that country. 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
